Development of a Targeted Mass-Spectrometry Serum Assay To Quantify M‑Protein in the Presence of Therapeutic Monoclonal Antibodies
journal contributionposted on 09.02.2018 by Marina Zajec, Joannes F. M. Jacobs, Patricia J. T. A. Groenen, Corrie M. de Kat Angelino, Christoph Stingl, Theo M. Luider, Yolanda B. De Rijke, Martijn M. VanDuijn
Any type of content formally published in an academic journal, usually following a peer-review process.
M-protein diagnostics can be compromised for patients receiving therapeutic monoclonal antibodies as treatment in multiple myeloma. Conventional techniques are often not able to distinguish between M-proteins and therapeutic monoclonal antibodies administered to the patient. This may prevent correct response assessment and can lead to overtreatment. We have developed a serum-based targeted mass-spectrometry assay to detect M-proteins, even in the presence of three therapeutic monoclonal antibodies (daratumumab, ipilimumab, and nivolumab). This assay can target proteotypic M-protein peptides as well as unique peptides derived from therapeutic monoclonal antibodies. We address the sensitivity in M-protein diagnostics and show that our mass-spectrometry assay is more than two orders of magnitude more sensitive than conventional M-protein diagnostics. The use of stable isotope-labeled peptides allows absolute quantification of the M-protein and increases the potential of assay standardization across multiple laboratories. Finally, we discuss the position of mass-spectrometry assays in monitoring minimal residual disease in multiple myeloma, which is currently dominated by molecular techniques based on plasma cell assessment that requires invasive bone marrow aspirations or biopsies.